scholarly journals Systemic lupus erythematosus in a multiethnic US cohort: Clinical features, course, and outcome in patients with late-onset disease

2006 ◽  
Vol 54 (5) ◽  
pp. 1580-1587 ◽  
Author(s):  
Ana M. Bertoli ◽  
Graciela S. Alarcón ◽  
Jaime Calvo-Alén ◽  
Mónica Fernández ◽  
Luis M. Vilá ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Systemic Lupus

Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register

2016 ◽  
Vol 36 (7) ◽  
pp. 955-960 ◽  
Author(s):  
S. Sousa ◽  
M. J. Gonçalves ◽  
L. S. Inês ◽  
G. Eugénio ◽  
D. Jesus ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Comparative Data ◽  
Long Term Outcomes ◽  
Systemic Lupus ◽  
National Register

Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study

2009 ◽  
Vol 37 (1) ◽  
pp. 38-44 ◽  
Author(s):  
SHELIZA LALANI ◽  
JANET POPE ◽  
FAYE de LEON ◽  
CHRISTINE PESCHKEN
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Control Group ◽  
Systemic Lupus ◽  
Damage Accrual ◽  
Onset Group ◽  
Onset Systemic Lupus Erythematosus

Objective.There is controversy whether older-onset systemic lupus erythematosus (SLE) is associated with a different, more benign disease course than in younger-onset SLE. Our objective was to characterize the clinical features and prognosis of late-onset SLE in a large, multicenter cohort.Methods.We studied adult-onset lupus in the 1000 Canadian Faces of Lupus cohort (n = 1528) of whom 10.5% had onset at age ≥ 50 years versus a control group with onset at < 50 years.Results.Disease duration was different in early- and late-onset groups (15 yrs in early vs 9.3 yrs in late; p < 0.001). Caucasians were represented more in the later-onset SLE group (55.6% vs 74.5%), while Asians and Blacks were more prevalent in the younger group. Younger-onset SLE subjects fulfilled more American College of Rheumatology criteria for SLE (< 50 yrs: 5.98 ± 1.68; ≥ 50 yrs: 5.24 ± 1.44; p < 0.0001). Despite an equal prevalence of anti-dsDNA, the younger-onset group more often had positive anti-Smith autoantibody, ribonucleoprotein, and hypocomplementemia, and more nephritis, rash, and cytopenias than the older-onset group. However, disease activity and damage accrual were higher in the older-onset group. The older patients received less prednisone and immunosuppressives (current and ever-use). As expected, comorbidity was higher in the older-onset SLE group.Conclusion.This study suggests that older age-onset SLE is not benign. There may be an interaction between lupus and age in which, although there is less lupus nephritis in the elderly, more disease activity and damage are present.

AB0636 Late-onset systemic lupus erythematosus: Clinical features, course and prognosis

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 675.4-675
Author(s):  
A. Tomic Lucic ◽  
R. Petrovic ◽  
M. Radak Perovic ◽  
D. Milovanovic ◽  
M. Veselinovic ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Systemic Lupus ◽  
Onset Systemic Lupus Erythematosus

scholarly journals FRI0183 DISTINCTIVE TRAITS OF MYOCARDIAL INFLAMMATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTRE STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 675.2-675
Author(s):  
G. A. Ramirez ◽  
M. Gerosa ◽  
G. De Luca ◽  
L. Beretta ◽  
S. Sala ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Early Onset ◽  
Disease Duration ◽  
Late Onset ◽  
Myocardial Inflammation ◽  
Systemic Lupus ◽  
Research Support

Background:Myocarditis is an infrequent but potentially life-threatening inflammatory disorder and might be part of the spectrum of systemic lupus erythematosus (SLE). Little is known about the clinical and histologic features of myocarditis in SLE, especially compared to other forms of myocarditis.Objectives:to test for potential distinctive traits among myocarditis in SLE (MyoSLE), SLE without myocarditis (OnlySLE) and myocarditis without SLE (OnlyMyo)Methods:Patients with MyoSLE were identified from three centres and compared with 231 cross-sectionally enrolled patients with OnlySLE and 87 patients with OnlyMyo. MyoSLE patients were split into two groups based on myocarditis onset within (early onset) vs after (late onset) the first year from SLE diagnosis. OnlySLE patients were dichotomised in the same way based on disease duration at time of enrolment. Demographics and general clinical features were collected retrospectively. SLE disease activity index 2000 (SLEDAI-2K), SLE International Collaborating Clinics/American College of Rheumatology damage index (SDI), clinical and laboratory features were collected at time of myocarditis onset in MyoSLE and at enrolment in OnlySLE. Quantitative data are expressed as median [interquartile range].Results:Fourteen MyoSLE patients were identified, 50% with early onset. Women were equally frequent among MyoSLE (71%) and OnlySLE patients (87%) and less frequent in the OnlyMyo group (43%; p<0.001). Age was comparable among groups. Clinical features at presentation, including left ventricular ejection fraction, were similar between MyoSLE and OnlyMyo, although the former had higher levels of pro-brain natriuretic peptide (1.1 [0.4-1.8] vs 0.1 [0.1-0.5] ng/ml; p=0.004). Patients with MyoSLE also had a lower frequency of left ventricle lateral wall involvement (36 vs 68%; p=0.035) and of oedema (20 vs 71%; p=0.036) and necrosis (0 vs 64%; p=0.009) at biopsy. Antiphospholipid antibodies (aPL) were more frequent in MyoSLE (57%) compared to both OnlyMyo (16%; p=0.003) and OnlySLE (28%; p=0.031). Compared to OnlySLE, patients with MyoSLE also had a higher prevalence of aPL-syndrome (APS: 36 vs 7%; p=0.003), neuropsychiatric (NPSLE: 43 vs 19%; p=0.039) and gastrointestinal manifestations (21 vs 5%; p=0.045). Early and late onset patients had similar demographics and clinical features and did not differ from patients with OnlySLE with similar disease duration in terms of SLEDAI-2K and SDI. Late onset MyoSLE patients had a higher prevalence of NPSLE (57 vs 18%; p=0.026) and APS (57 vs 7%; p=0.001) and higher C-reactive protein levels (6 [2-12] vs 1[0-4] mg/l; p=0.024) compared to OnlySLE patients with the same disease duration.Conclusion:Demographics of patients with MyoSLE are more similar to patients with OnlySLE than to OnlyMyo patients. MyoSLE might have distinct histological and pathogenic features compared to OnlyMyo. Patients with MyoSLE show similar patterns of disease activity and accrued damage at time of myocarditis onset compared to patients with OnlySLE with the same disease duration but might diverge later on in SLE course. aPL are frequent in MyoSLE and might both contribute to the pathogenesis of myocardial inflammation and account for the high prevalence of NPSLE and APS, especially in late onset cases.References:[1]Gartshteyn Y et al., Lupus, 2020[2]Thomas G et al., J Rheumatol, 2017[3]Peretto G et al., Int J Cardiol, 2019[4]McDonnell T et al., Blood Rev, 2019Disclosure of Interests:Giuseppe Alvise Ramirez: None declared, Maria Gerosa: None declared, Giacomo De Luca Speakers bureau: SOBI, Novartis, Celgene, Pfizer, MSD, Lorenzo Beretta Grant/research support from: Pfizer, Simone Sala: None declared, Giovanni Peretto: None declared, Luca Moroni: None declared, Francesca Mastropaolo: None declared, adriana cariddi: None declared, Silvia Sartorelli: None declared, Corrado Campochiaro Speakers bureau: Novartis, Pfizer, Roche, GSK, SOBI, Enrica Bozzolo: None declared, Roberto Caporali Consultant of: AbbVie; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Celgene; Bristol-Myers Squibb; Pfizer; UCB, Speakers bureau: Abbvie; Bristol-Myers Squibb; Celgene; Lilly; Gilead Sciences, Inc; MSD; Pfizer; Roche; UCB, Lorenzo Dagna Grant/research support from: The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unresctricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI., Consultant of: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI.

Late-onset systemic lupus erythematosus: clinical features, course, and prognosis

2013 ◽  
Vol 32 (7) ◽  
pp. 1053-1058 ◽  
Author(s):  
Aleksandra Tomic-Lucic ◽  
Radmila Petrovic ◽  
Marija Radak-Perovic ◽  
Dragan Milovanovic ◽  
Jasmina Milovanovic ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Systemic Lupus ◽  
Onset Systemic Lupus Erythematosus

Late onset systemic lupus erythematosus with elevated CA125 and gastrointestinal ischaemia

2002 ◽  
Vol 32 (3) ◽  
pp. 117-118 ◽  
Author(s):  
M. S. Koh ◽  
K. Sunil ◽  
H. S. Howe
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Systemic Lupus ◽  
Onset Systemic Lupus Erythematosus

Autoimmune hepatitis complicated by late-onset systemic lupus erythematosus

2007 ◽  
Vol 37 (9) ◽  
pp. 771-774 ◽  
Author(s):  
Atsushi Takahashi ◽  
Tsuyoshi Rai ◽  
Michio Onizawa ◽  
Kyoko Monoe ◽  
Yukiko Kanno ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Hepatitis ◽  
Lupus Erythematosus ◽  
Late Onset ◽  
Systemic Lupus ◽  
Onset Systemic Lupus Erythematosus

THE FREQUENT OCCURRENCE OF NEUROLOGICAL DISEASE IN PATIENTS WITH LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS

Rheumatology ◽  
1984 ◽  
Vol 23 (3) ◽  
pp. 186-189 ◽  
Author(s):  
KENNETH MCDONALD ◽  
MICHAEL HUTCHINSON ◽  
BARRY BRESNIHAN
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Neurological Disease ◽  
Late Onset ◽  
Frequent Occurrence ◽  
Systemic Lupus ◽  
Onset Systemic Lupus Erythematosus
Sign in / Sign up

Export Citation Format

Share Document